Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.09 CNY | -0.41% |
|
-0.45% | -10.12% |
| Capitalization | 40.49B 5.75B 4.89B 4.57B 4.29B 7.91B 521B 8.64B 53.3B 20.6B 245B 21.56B 21.11B 892B | P/E ratio 2025 * |
30.9x | P/E ratio 2026 * | 30.9x |
|---|---|---|---|---|---|
| Enterprise value | 39.61B 5.62B 4.78B 4.47B 4.2B 7.74B 510B 8.45B 52.14B 20.15B 240B 21.09B 20.65B 873B | EV / Sales 2025 * |
5.76x | EV / Sales 2026 * | 5.05x |
| Free-Float |
72.37% | Yield 2025 * |
1.04% | Yield 2026 * | 1% |
| 1 day | -0.41% | ||
| 1 week | -0.45% | ||
| Current month | -3.76% | ||
| 1 month | -15.22% | ||
| 3 months | -20.53% | ||
| 6 months | -6.50% | ||
| Current year | -10.12% |
| 1 week | 48.6 |  | 50.66 |
| 1 month | 47.9 | | 57.7 |
| Current year | 41.61 | | 71.9 |
| 1 year | 41.61 | | 71.9 |
| 3 years | 36.12 | | 130 |
| 5 years | 36.12 | | 209.41 |
| 10 years | 14.2 | | 209.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 56 | - |
Cheng Cheng Yang
DFI | Director of Finance/CFO | 51 | 2022-10-20 |
Hao Wu
PSD | President | 58 | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Xiao Chun Cao
BRD | Director/Board Member | 56 | 2004-12-31 |
Xiao Ping Ye
CHM | Chairman | 62 | - |
Zhi Min Chen
BRD | Director/Board Member | 65 | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.41% | -0.45% | -21.51% | -46.29% | 5.75B | |
| -0.78% | -4.14% | -4.87% | +15.38% | 46.18B | |
| -1.17% | +1.58% | +12.39% | +8.70% | 38.08B | |
| -2.16% | -4.55% | +72.51% | +48.38% | 34.38B | |
| -1.17% | -0.80% | +4.80% | +17.43% | 27.99B | |
| -1.16% | +1.91% | +58.54% | +169.16% | 15.75B | |
| -3.41% | -1.85% | +70.81% | +214.28% | 15.27B | |
| -1.28% | +0.71% | -10.58% | -2.32% | 14.08B | |
| -3.67% | +4.64% | +50.62% | +73.48% | 13.03B | |
| -2.18% | -1.28% | +104.33% | +101.37% | 12.92B | |
| Average | -1.77% | -0.86% | +33.70% | +59.96% | 22.34B | |
| Weighted average by Cap. | -1.63% | -1.58% | +29.59% | +49.67% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.87B 975M 829M 776M 729M 1.34B 88.45B 1.47B 9.04B 3.5B 41.63B 3.66B 3.58B 151B | 7.82B 1.11B 944M 883M 830M 1.53B 101B 1.67B 10.3B 3.98B 47.4B 4.17B 4.08B 172B |
| Net income | 1.31B 186M 158M 148M 139M 256M 16.86B 280M 1.72B 666M 7.93B 697M 683M 28.85B | 1.46B 207M 176M 165M 155M 285M 18.8B 312M 1.92B 743M 8.85B 777M 761M 32.17B |
| Net Debt | -882M -125M -106M -99.56M -93.5M -172M -11.35B -188M -1.16B -449M -5.34B -469M -460M -19.43B | -990M -140M -119M -112M -105M -193M -12.74B -211M -1.3B -504M -6B -527M -516M -21.81B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-15 | 49.09 ¥ | -0.41% | 6,338,318 |
| 25-12-15 | 49.29 ¥ | -1.97% | 7,825,358 |
| 25-12-12 | 50.28 ¥ | +2.22% | 11,248,870 |
| 25-12-11 | 49.19 ¥ | -1.40% | 6,673,753 |
| 25-12-10 | 49.89 ¥ | +0.26% | 7,524,265 |
End-of-day quote Shenzhen S.E., December 15, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300347 Stock
Select your edition
All financial news and data tailored to specific country editions
